Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

The simian immunodeficiency virus (SIV) challenge model of lentiviral infection is often used as a model to human immunodeficiency virus type 1 (HIV-1) for studying vaccine mediated and immune correlates of protection. However, knowledge of the structure of the SIV envelope (Env) glycoprotein is limited, as is knowledge of binding specificity, function and potential efficacy of SIV antibody responses. In this study we describe the use of a competitive probe binding sort strategy as well as scaffolded probes for targeted isolation of SIV Env-specific monoclonal antibodies (mAbs). We isolated nearly 70 SIV-specific mAbs directed against major sites of SIV Env vulnerability analogous to broadly neutralizing antibody (bnAb) targets of HIV-1, namely, the CD4 binding site (CD4bs), CD4-induced (CD4i)-site, peptide epitopes in variable loops 1, 2 and 3 (V1, V2, V3) and potentially glycan targets of SIV Env. The range of SIV mAbs isolated includes those exhibiting varying degrees of neutralization breadth and potency as well as others that demonstrated binding but not neutralization. Several SIV mAbs displayed broad and potent neutralization of a diverse panel of 20 SIV viral isolates with some also neutralizing HIV-27312A. This extensive panel of SIV mAbs will facilitate more effective use of the SIV non-human primate (NHP) model for understanding the variables in development of a HIV vaccine or immunotherapy.

[1]  E. Hunter,et al.  Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses , 2015, Proceedings of the National Academy of Sciences.

[2]  H. Schuitemaker,et al.  Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys , 2015, Science.

[3]  G. Nabel,et al.  Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014. , 2015, Vaccine.

[4]  B. Pulendran,et al.  Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope , 2015, Journal of Virology.

[5]  John R Mascola,et al.  Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.

[6]  L. Morris,et al.  HIV broadly neutralizing antibody targets , 2015, Current opinion in HIV and AIDS.

[7]  T. Kepler,et al.  Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization , 2015, Nature Communications.

[8]  Gwo-Yu Chuang,et al.  Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.

[9]  Y. Guan,et al.  Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1 , 2014, Front. Immunol..

[10]  James C Paulson,et al.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.

[11]  G. Alter,et al.  Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies , 2014, PloS one.

[12]  Han Gao,et al.  Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. , 2014, Cell reports.

[13]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[14]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[15]  David Baker,et al.  Proof of principle for epitope-focused vaccine design , 2014, Nature.

[16]  Richard Wilson,et al.  Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign , 2014, Proceedings of the National Academy of Sciences.

[17]  Mario Roederer,et al.  Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV , 2013, Nature.

[18]  L. Stamatatos,et al.  Diverse Recombinant HIV-1 Envs Fail To Activate B Cells Expressing the Germline B Cell Receptors of the Broadly Neutralizing Anti-HIV-1 Antibodies PG9 and 447-52D , 2013, Journal of Virology.

[19]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[20]  M. Nussenzweig,et al.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.

[21]  Jerome H. Kim,et al.  Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.

[22]  John P. Moore,et al.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation , 2013, Proceedings of the National Academy of Sciences.

[23]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[24]  J. Mascola,et al.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.

[25]  Youdong Mao,et al.  A Twin-Cysteine Motif in the V2 Region of gp120 Is Associated with SIV Envelope Trimer Stabilization , 2013, PloS one.

[26]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[27]  B. Haynes,et al.  Progress in HIV-1 vaccine development , 2013, Current opinion in HIV and AIDS.

[28]  Tongqing Zhou,et al.  Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.

[29]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[30]  G. Learn,et al.  Heterogeneity in Neutralization Sensitivities of Viruses Comprising the Simian Immunodeficiency Virus SIVsmE660 Isolate and Vaccine Challenge Stock , 2013, Journal of Virology.

[31]  L. Morris,et al.  Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies , 2013, Journal of Virology.

[32]  H. Robinson Non-neutralizing antibodies in prevention of HIV infection , 2013, Expert opinion on biological therapy.

[33]  L. Stamatatos,et al.  Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS pathogens.

[34]  S. Self,et al.  Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. , 2012, Journal of immunological methods.

[35]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[36]  Bin Li,et al.  Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. , 2012, Virology.

[37]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[38]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[39]  M. Hassall,et al.  Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model , 2012, Retrovirology.

[40]  J. Mascola,et al.  Envelope Variable Region 4 Is the First Target of Neutralizing Antibodies in Early Simian Immunodeficiency Virus mac251 Infection of Rhesus Monkeys , 2012, Journal of Virology.

[41]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[42]  Young Do Kwon,et al.  Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops , 2012, Proceedings of the National Academy of Sciences.

[43]  B. Korber,et al.  Distinct Evolutionary Pressures Underlie Diversity in Simian Immunodeficiency Virus and Human Immunodeficiency Virus Lineages , 2012, Journal of Virology.

[44]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[45]  John P. Moore,et al.  SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses , 2011, PloS one.

[46]  Young Do Kwon,et al.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.

[47]  S. Rowland-Jones,et al.  Potent Autologous and Heterologous Neutralizing Antibody Responses Occur in HIV-2 Infection across a Broad Range of Infection Outcomes , 2011, Journal of Virology.

[48]  F. Månsson,et al.  Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1 , 2011, Journal of Virology.

[49]  G. Gottlieb,et al.  Broad and Potent Neutralizing Antibody Responses Elicited in Natural HIV-2 Infection , 2011, Journal of Virology.

[50]  T. Kepler,et al.  Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting , 2011, PloS one.

[51]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[52]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[53]  Jamie K. Scott,et al.  Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies , 2011, Journal of Virology.

[54]  T. Kepler,et al.  Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.

[55]  Barney S. Graham,et al.  Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.

[56]  John P. Moore,et al.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody , 2011, Proceedings of the National Academy of Sciences.

[57]  R. Wyatt,et al.  Direct Antibody Access to the HIV-1 Membrane-Proximal External Region Positively Correlates with Neutralization Sensitivity , 2011, Journal of Virology.

[58]  Véronique Giudicelli,et al.  IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. , 2011, Cold Spring Harbor protocols.

[59]  M. Hudgens,et al.  Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys , 2011, Science Translational Medicine.

[60]  J. Kappes,et al.  An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum , 2011, Journal of Virology.

[61]  D. Montefiori,et al.  Significant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen , 2011, Journal of Virology.

[62]  D. Venzon,et al.  Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. , 2011, Vaccine.

[63]  Jamie K. Scott,et al.  Comparison of Antibody Repertoires Produced by HIV-1 Infection, Other Chronic and Acute Infections, and Systemic Autoimmune Disease , 2011, PloS one.

[64]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[65]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[66]  C. Andrews,et al.  Genetic immunization in the lung induces potent local and systemic immune responses , 2010, Proceedings of the National Academy of Sciences.

[67]  T. Miura,et al.  Isolation of potent neutralizing monoclonal antibodies from an SIV-Infected rhesus macaque by phage display. , 2010, AIDS research and human retroviruses.

[68]  R. Desrosiers,et al.  Diversity of envelope genes from an uncloned stock of SIVmac251. , 2010, AIDS research and human retroviruses.

[69]  N. Haigwood,et al.  Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques , 2010, Nature Medicine.

[70]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[71]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[72]  Dennis R. Burton,et al.  Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16 , 2010, Journal of Virology.

[73]  R. Koup,et al.  Amine‐Reactive Dyes for Dead Cell Discrimination in Fixed Samples , 2010, Current protocols in cytometry.

[74]  B. Korber,et al.  Autologous Neutralizing Antibodies to the Transmitted/Founder Viruses Emerge Late after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys , 2010, Journal of Virology.

[75]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[76]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[77]  Tongqing Zhou,et al.  Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.

[78]  A. Perelson,et al.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection , 2009, The Journal of experimental medicine.

[79]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[80]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[81]  J. Sodroski,et al.  Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State , 2009, PLoS pathogens.

[82]  K. Abel,et al.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study , 2009, Human vaccines.

[83]  B. Korber,et al.  Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate , 2009, Journal of Virology.

[84]  J. Heeney,et al.  Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. , 2008, Virology.

[85]  Marie-Paule Lefranc,et al.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis , 2008, Nucleic Acids Res..

[86]  R. Gallo,et al.  Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens , 2007, Proceedings of the National Academy of Sciences.

[87]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[88]  J. Mascola,et al.  A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates , 2005, Journal of Virology.

[89]  R. Wyatt,et al.  Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. , 2005, Virology.

[90]  J. Sodroski,et al.  Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[91]  D. Burton,et al.  Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities , 2003, Journal of Virology.

[92]  J. Sodroski,et al.  Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.

[93]  Gianni Cesareni,et al.  Unusual Binding Properties of the SH3 Domain of the Yeast Actin-binding Protein Abp1 , 2002, The Journal of Biological Chemistry.

[94]  J. Robinson,et al.  Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. , 2001, Virology.

[95]  M. Malim,et al.  Ability of the V3 Loop of Simian Immunodeficiency Virus To Serve as a Target for Antibody-Mediated Neutralization: Correlation of Neutralization Sensitivity, Growth in Macrophages, and Decreased Dependence on CD4 , 2001, Journal of Virology.

[96]  C. Bewley,et al.  The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. , 2001, Journal of the American Chemical Society.

[97]  R. Doms,et al.  Characterization and Epitope Mapping of Neutralizing Monoclonal Antibodies Produced by Immunization with Oligomeric Simian Immunodeficiency Virus Envelope Protein , 2000, Journal of Virology.

[98]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[99]  Q. Sattentau,et al.  Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120 , 1999, Journal of Virology.

[100]  D. Montefiori,et al.  Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. , 1998, AIDS research and human retroviruses.

[101]  J. Robinson,et al.  Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. , 1998, AIDS research and human retroviruses.

[102]  L. Pannell,et al.  Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. , 1998, Protein expression and purification.

[103]  D. Dormont,et al.  Production and characterization of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1997, AIDS research and human retroviruses.

[104]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.

[105]  D. Montefiori,et al.  The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. , 1996, Virology.

[106]  K. Kent Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein , 1995, Journal of medical primatology.

[107]  R. Desrosiers,et al.  Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity , 1994, Journal of virology.

[108]  E. Rud,et al.  Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. , 1992, AIDS research and human retroviruses.

[109]  L. Gritz,et al.  Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1991, AIDS.

[110]  R. Garlick,et al.  Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. , 1990, AIDS research and human retroviruses.

[111]  L. Morris,et al.  The Antibody Response against HIV-1. , 2012, Cold Spring Harbor perspectives in medicine.

[112]  J. Sodroski,et al.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. , 1992, Journal of acquired immune deficiency syndromes.